CD38 Inhibition + NAD+ Precursor Synergy for Neuroprotection
📖 Wiki Page
idea1282 wordssynced 2026-04-02
Overview
Executive Summary
Target: CD38/CD157 ectoenzymes + NAD+ biosynthesis [@bonafede2020]
Approach: Combine CD38 inhibitors with NAD+ precursors to achieve greater NAD+ repletion than either approach alone [@tarrago2021]
Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Aging [@hou2016]
Score: 77/100
Mechanism of Action
CD38 Biology
CD38 is a transmembrane glycoprotein that functions as an ecto-NADase, hydrolyzing NAD+ to nicotinamide (NAM) and cyclic ADP-ribose (cADPR). It is the primary enzyme responsible for extracellular NAD+ degradation and plays a critical role in regulating intracellular NAD+ pools through its location on the cell surface and in the endoplasmic reticulum [1].
Key CD38 effects:
Hydrolyzes intracellular and extracellular NAD+
Produces cADPR, a calcium-mobilizing second messenger
Regulates mitochondrial function through NAD+ availability
Increases with age - major contributor to NAD+ decline [2]
Therapeutic Rationale
In aging and neurodegeneration, CD38 expression increases in multiple tissues including brain [3]:
Alzheimer's: CD38 elevated in [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes); contributes to NAD+ depletion
Aging: CD38 activity increases ~2-3x in brain and peripheral tissues by age 60+
...
Overview
Executive Summary
Target: CD38/CD157 ectoenzymes + NAD+ biosynthesis [@bonafede2020]
Approach: Combine CD38 inhibitors with NAD+ precursors to achieve greater NAD+ repletion than either approach alone [@tarrago2021]
Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Aging [@hou2016]
Score: 77/100
Mechanism of Action
CD38 Biology
CD38 is a transmembrane glycoprotein that functions as an ecto-NADase, hydrolyzing NAD+ to nicotinamide (NAM) and cyclic ADP-ribose (cADPR). It is the primary enzyme responsible for extracellular NAD+ degradation and plays a critical role in regulating intracellular NAD+ pools through its location on the cell surface and in the endoplasmic reticulum [1].
Key CD38 effects:
Hydrolyzes intracellular and extracellular NAD+
Produces cADPR, a calcium-mobilizing second messenger
Regulates mitochondrial function through NAD+ availability
Increases with age - major contributor to NAD+ decline [2]
Therapeutic Rationale
In aging and neurodegeneration, CD38 expression increases in multiple tissues including brain [3]:
Alzheimer's: CD38 elevated in [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes); contributes to NAD+ depletion
Aging: CD38 activity increases ~2-3x in brain and peripheral tissues by age 60+
CD38 inhibitors (e.g., apigenin, 78c, AZD0305) have shown [4]:
NAD+ preservation in preclinical models
Enhanced SIRT1 activity
Improved mitochondrial function
However, CD38 inhibition alone may be insufficient because:
Basal NAD+ biosynthesis remains impaired
Other NAD+-consuming enzymes (PARPs, SARM1) still deplete pools
The synergy: CD38 inhibition prevents NAD+ breakdown while precursors (NMN, NR) boost biosynthesis. Combined effect > sum of parts.
Scoring (10-Dimension Rubric)
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 8 | CD38 inhibition is newer; combination not yet in trials | | Mechanistic Rationale | 9 | Strong validation for CD38 role in NAD+ decline | | Root-Cause Coverage | 8 | Addresses both NAD+ consumption and biosynthesis | | Delivery Feasibility | 7 | Small molecule inhibitors; brain penetration variable | | Safety Plausibility | 8 | CD38 knockout mice are healthy; therapeutic window exists | | Combinability | 9 | Works with SIRT1 activators, [autophagy](/entities/autophagy) enhancers | | Biomarker Availability | 8 | NAD+ levels, CD38 activity, cADPR measurable | | De-risking Path | 7 | Can use existing CD38 inhibitor scaffolds | | Multi-disease Potential | 8 | AD, PD, aging, metabolic disease | | Patient Impact | 7 | Addresses fundamental metabolic deficit |
Total: 77/100
Actionable Next Steps
Lab Experiments
CD38 inhibitor brain penetration screening: Test existing CD38 inhibitors (apigenin, 78c, AZD0305) in in vitro [BBB](/entities/blood-brain-barrier) models and in vivo PK/PD in rodents to identify CNS-penetrant leads
NAD+ precursor combination testing: Combine CD38 inhibitors with NAD+ precursors (NMN, NR) in iPSC-derived [neurons](/entities/neurons) from AD/PD patients to measure NAD+ levels, SIRT1 activity, and mitochondrial function
Biomarker validation: Establish CD38 activity in CSF and peripheral blood mononuclear cells (PBMCs) as pharmacodynamic markers
Clinical Protocol Design
Enrichment strategy: Select patients with elevated CD38 expression or confirmed NAD+ deficiency in CSF
Dose-finding design: Start with low-dose CD38 inhibitor (apigenin 50mg daily or 78c 10mg daily) combined with NAD+ precursor (NMN 250mg daily)
Combination protocol: Consider adding SIRT1 activator after CD38 inhibitor loading for maximum NAD+ repletion
Company Partnership Opportunities
Calico/Alapagos (AZD0305): Partner for CD38 inhibitor development and CNS indication
ChromaDex (NR): Partner for NAD+ precursor supply and clinical development
Aberla/Cartherics: Partner for CD38 antibody therapeutics with brain penetration
Tesoro/Beacon: Partner for biomarker development
Combination Therapy Opportunities
Synergistic Targets
+ SIRT1 Activators: Maximum NAD+ availability for sirtuin activity
+ Autophagy Inducers (TFEB): Enhanced autophagy with preserved NAD+
+ PARP Inhibitors: Prevent NAD+ consumption from DNA repair